Cargando…

Primary fibroblastic osteosarcoma of sternum: A case report

RATIONALE: Osteosarcoma, a malignant bone tumor, rarely occurs in the sternum, especially the fibroblastic type, and is associated with poor survival. This case report describes a patient with a neoplasm of the sternum who underwent tumor resection 3 times and reconstruction twice because of the hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shaozi, Zhou, Yile, Xu, Heyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282063/
https://www.ncbi.nlm.nih.gov/pubmed/35363174
http://dx.doi.org/10.1097/MD.0000000000028827
Descripción
Sumario:RATIONALE: Osteosarcoma, a malignant bone tumor, rarely occurs in the sternum, especially the fibroblastic type, and is associated with poor survival. This case report describes a patient with a neoplasm of the sternum who underwent tumor resection 3 times and reconstruction twice because of the high risk of recurrence. PATIENT CONCERNS: A 60-year-old Chinese man presented with a 3-cm palpable bulging mass located in front of his sternum. Chest computed tomography (CT) revealed an anterior chest wall neoplasm with sternal destruction. DIAGNOSIS: Pathological examination revealed that the mass was a low-grade malignant primary fibroblastic osteosarcoma. INTERVENTIONS: Locking plates were used for chest wall reconstruction, demonstrating good structural stability and economic applicability. Regarding the ineffectiveness of current therapies, whole-exome sequencing was conducted, and no targets matched any of the currently available agents. OUTCOMES: No recurrence was found on regular reexamination. LESSONS: Surgery is the first choice of treatment for patients with primary fibroblastic osteosarcoma of the sternum. The reconstruction-locking plate is a good alternative for chest wall reconstruction. Whole-exome sequencing can shed new light on this uncommon disease and help identify novel therapeutic targets.